Twist Bioscience Co. (NASDAQ:TWST) CAO Sells $11,910.20 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner sold 226 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $11,910.20. Following the transaction, the chief accounting officer now owns 53,043 shares of the company’s stock, valued at approximately $2,795,366.10. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $47.39 on Friday. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company’s fifty day moving average price is $44.85 and its two-hundred day moving average price is $46.60.

Wall Street Analyst Weigh In

Several research firms recently commented on TWST. Evercore ISI increased their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen reiterated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays decreased their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Robert W. Baird boosted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Finally, Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience during the third quarter worth approximately $34,000. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the 2nd quarter worth $43,000. Blue Trust Inc. lifted its holdings in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the second quarter valued at about $61,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.